Back to top

Image: Bigstock

Top Ranked Momentum Stocks to Buy for November 9th

Read MoreHide Full Article

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 9th:

Criteo S.A. (CRTO - Free Report) : This advertising platform for the open Internet has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 22.6% over the last 60 days.

 

Criteo S.A. Price and Consensus

Criteo S.A. Price and Consensus

Criteo S.A. price-consensus-chart | Criteo S.A. Quote

 

Criteo’s shares gained 32.4% over the last one month compared with the S&P 500’s growth of 1.8%. The company possesses a Momentum Score of A.

 

Kontoor Brands, Inc. (KTB - Free Report) : This lifestyle apparel company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 65% over the last 60 days.

 

Kontoor Brands’ shares gained 24.7% over the last one month. The company possesses a Momentum Score of A.

 

Bunge Limited (BG - Free Report) : This agribusiness and food company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 62.9% over the last 60 days.

 

Bunge Limited Price and Consensus

Bunge Limited Price and Consensus

Bunge Limited price-consensus-chart | Bunge Limited Quote

 

Bunge’s shares gained 17.3% over the last one month. The company possesses a Momentum Score of A.

 

Alliance Resource Partners, L.P. (ARLP - Free Report) : This diversified natural resource company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 31.8% over the last 60 days.

 

Alliance Resource Partners’ shares gained 14.8% over the last one month. The company possesses a Momentum Score of A.

 

See the full list of top ranked stocks here.

Learn more about the Momentum score and how it is calculated here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>